- Home
- GRDI vs RFL Comparison
GRDI vs RFL Comparison
Compare GRDI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRDI
- RFL
- Stock Information
- Founded
- GRDI 2018
- RFL 2017
- Country
- GRDI United States
- RFL United States
- Employees
- GRDI N/A
- RFL N/A
- Industry
- GRDI
- RFL Real Estate
- Sector
- GRDI
- RFL Finance
- Exchange
- GRDI NYSE
- RFL Nasdaq
- Market Cap
- GRDI 53.9M
- RFL 48.4M
- IPO Year
- GRDI N/A
- RFL N/A
- Fundamental
- Price
- GRDI $0.77
- RFL $2.11
- Analyst Decision
- GRDI
- RFL
- Analyst Count
- GRDI 0
- RFL 0
- Target Price
- GRDI N/A
- RFL N/A
- AVG Volume (30 Days)
- GRDI 36.7K
- RFL 48.8K
- Earning Date
- GRDI 01-01-0001
- RFL 10-28-2024
- Dividend Yield
- GRDI N/A
- RFL N/A
- EPS Growth
- GRDI N/A
- RFL N/A
- EPS
- GRDI 0.35
- RFL N/A
- Revenue
- GRDI $20,943,000.00
- RFL $540,000.00
- Revenue This Year
- GRDI N/A
- RFL N/A
- Revenue Next Year
- GRDI N/A
- RFL N/A
- P/E Ratio
- GRDI $2.67
- RFL N/A
- Revenue Growth
- GRDI 8.57
- RFL 92.86
- 52 Week Low
- GRDI $0.56
- RFL $1.29
- 52 Week High
- GRDI $9.66
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- GRDI 40.64
- RFL 79.64
- Support Level
- GRDI $0.70
- RFL $1.65
- Resistance Level
- GRDI $0.78
- RFL $1.94
- Average True Range (ATR)
- GRDI 0.07
- RFL 0.10
- MACD
- GRDI 0.00
- RFL 0.02
- Stochastic Oscillator
- GRDI 32.60
- RFL 98.79
About GRDI GRIID INFRASTRUCTURE INC
Griid Holdco LLC is a vertically integrated Bitcoin mining company. It owns and operates a growing portfolio of energy infrastructure and high-density data centers across North America. The Company has built a cryptocurrency mining operation, which operates specialized computers (also known as miners) that generate cryptocurrency. Currently, the only cryptocurrency mined by GRIID is Bitcoin.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.